deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02947438

Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study) (BEAT_002)

A Prospective, Randomized, Double Blind, Parallel Group Study to Evaluate a 1:1 Dose Conversion From EPREX to EPIAO in Term of Clinical Efficacy and Safety in Subjects With End-Stage Renal Disease on Haemodialysis

Sponsor: Navitas Life Sciences GmbH

Conditions Renal Anemia
Interventions EPIAO® EPREX®
Updated 11 times since 2017 Last updated: Nov 18, 2022 Started: Dec 31, 2015 Primary completion: Oct 9, 2021 Completion: Oct 9, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Renal Anemia, this trial is completed. The trial is conducted by Navitas Life Sciences GmbH and has accumulated 11 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotRecruiting~Jun 2018 – ~May 2020 · 23 months · monthly snapshotRecruiting~May 2020 – ~Jul 2020 · 2 months · monthly snapshotUnknown Status~Jul 2020 – ~Nov 2020 · 4 months · monthly snapshotUnknown Status~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotRecruiting~Jan 2021 – ~Nov 2022 · 22 months · monthly snapshotRecruiting~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshotUnknown Status~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Unknown Status → Completed

  5. Nov 2022 — Dec 2022 [monthly]

    Unknown Status PHASE3

    Status: Recruiting → Unknown Status

▶ Show 6 earlier versions

  1. Jan 2021 — Nov 2022 [monthly]

    Recruiting PHASE3

  2. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

    Status: Unknown Status → Recruiting

  3. Jul 2020 — Nov 2020 [monthly]

    Unknown Status PHASE3

  4. May 2020 — Jul 2020 [monthly]

    Unknown Status PHASE3

    Status: Recruiting → Unknown Status

  5. Jun 2018 — May 2020 [monthly]

    Recruiting PHASE3

    Phase: PHASE4 → PHASE3

  6. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE4

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Navitas Life Sciences GmbH
  • Shenyang Sunshine Pharmaceutical Co., LTD.
Data source: Shenyang Sunshine Pharmaceutical Co., LTD.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations